ACVRL1 and breast cancer: In conclusion, our work uncovers that ALK1 embodies a dual angiogenic and immunomodulatory function in breast cancer, thereby providing a rationale for the reevaluation of ALK1-blocking agents in combination with immune checkpoint blockade.